Experimental T-Cell Therapy Shows Early Efficacy Against Resistant Cancers

Early clinical trial results for invikafusp alfa, a precision T-cell therapy, indicate its potential against cancers resistant to standard treatments. The experimental drug, studied by NIH and other institutions, successfully halted disease progression in most patients and shrank tumors in some, while being well tolerated. This development offers a new therapeutic avenue for individuals with refractory solid tumors.